Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
However, recent clinical studies are now beginning to explore their potential role in managing gastrointestinal and inflammatory conditions
Early phase 2 data showed average weight loss of approximately 24 percent at 48 weeks, with the STEP UP trial demonstrating 20.7 percent average weight reduction with the higher dose formulation at 72 weeks
As of early 2026, retatrutide is not yet FDA approved
doi:10.1002/oby.24331
and SURMOUNT-MMO (NCT05556512), involving individuals who are overweight or obese
Exosomal miR-4449 derived from DKD patient serum substantially accelerates tubular epithelial cell pyroptosis and oxidative stress through the transcriptional suppression of HIC1, leading to GSDMD-mediated pore formation and inflammatory cytokine secretion (167)
US$ 24.32
US$ 25.00
US$ 21.71
US$ 25.73
US$ 22.47
US$ 28.77
US$ 29.36
US$ 21.76
US$ 21.77
US$ 24.66
